These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22970943)

  • 1. There is more to life than death.
    Hartzband P; Groopman J
    N Engl J Med; 2012 Sep; 367(11):987-9. PubMed ID: 22970943
    [No Abstract]   [Full Text] [Related]  

  • 2. Lung cancer screening gets risk-specific.
    Peres J
    J Natl Cancer Inst; 2013 Jan; 105(1):1-2. PubMed ID: 23257155
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Belpomme D; Irigaray P
    J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate-specific antigen dynamics and prostate cancer diagnosis.
    Bartoletti R
    Eur Urol; 2009 Nov; 56(5):761-2; discussion 763. PubMed ID: 19665286
    [No Abstract]   [Full Text] [Related]  

  • 5. Epilogue: different approaches for prostate cancer screening in the EU?
    Schröder FH; Denis L; Roobol MJ
    Eur J Cancer; 2010 Nov; 46(17):3120-5. PubMed ID: 21047595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Communicating benefits and risks of screening for prostate, colon, and breast cancer.
    Barrett B; McKenna P
    Fam Med; 2011 Apr; 43(4):248-53. PubMed ID: 21499997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solving the overdiagnosis dilemma.
    Esserman L; Thompson I
    J Natl Cancer Inst; 2010 May; 102(9):582-3. PubMed ID: 20413743
    [No Abstract]   [Full Text] [Related]  

  • 8. PSA at 60 may predict risk of death from prostate cancer.
    Rees J
    Practitioner; 2010 Oct; 254(1733):5. PubMed ID: 21141246
    [No Abstract]   [Full Text] [Related]  

  • 9. Numbers needed to decide.
    Woloshin S; Schwartz LM
    J Natl Cancer Inst; 2009 Sep; 101(17):1163-5. PubMed ID: 19671771
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?
    Carroll PR; Whitson JM; Cooperberg MR
    J Clin Oncol; 2011 Feb; 29(4):345-7. PubMed ID: 21189396
    [No Abstract]   [Full Text] [Related]  

  • 11. Divergent Responses to Mammography and Prostate-Specific Antigen Recommendations.
    Martinez KA; Rothberg MB
    Am J Prev Med; 2017 Oct; 53(4):533-536. PubMed ID: 28318901
    [No Abstract]   [Full Text] [Related]  

  • 12. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 13. Screening for prostate cancer remains controversial.
    Stark JR; Mucci L; Rothman KJ; Adami HO
    BMJ; 2009 Sep; 339():b3601. PubMed ID: 19778971
    [No Abstract]   [Full Text] [Related]  

  • 14. What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation.
    Catalona WJ; D'Amico AV; Fitzgibbons WF; Kosoko-Lasaki O; Leslie SW; Lynch HT; Moul JW; Rendell MS; Walsh PC
    Ann Intern Med; 2012 Jul; 157(2):137-8. PubMed ID: 22801676
    [No Abstract]   [Full Text] [Related]  

  • 15. The phantom menace of prostate cancer screening.
    Ghani KR; Trinh QD; Menon M
    BJU Int; 2012 Feb; 109(3):324-6. PubMed ID: 22243666
    [No Abstract]   [Full Text] [Related]  

  • 16. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010.
    ;
    Int J Urol; 2010 Oct; 17(10):830-8. PubMed ID: 20825509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balancing the harms and benefits of early detection of prostate cancer.
    van Leeuwen PJ; Connolly D; Tammela TL; Auvinen A; Kranse R; Roobol MJ; Schroder FH; Gavin A
    Cancer; 2010 Oct; 116(20):4857-65. PubMed ID: 20839233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Public knowledge of benefits of breast and prostate cancer screening in Europe.
    Brenner H; Heywang-Köbrunner S; Becker N
    J Natl Cancer Inst; 2010 Mar; 102(5):356; author reply 356-7. PubMed ID: 20075365
    [No Abstract]   [Full Text] [Related]  

  • 19. Task force's prevention advice proves hard to swallow. Interview by Eliot Marshall.
    Moyer V
    Science; 2012 Sep; 337(6101):1468-70. PubMed ID: 22997318
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States: A Nationwide Survey Analysis.
    Abdollah F; Sun M; Sammon JD; Choueiri TK; Menon M; Weissman JS; Trinh QD
    JAMA Oncol; 2016 Apr; 2(4):543-5. PubMed ID: 26794060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.